Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 404 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Worries About Medical Bills May Worsen Health Outcomes After Cancer Diagnosis March 13, 2021 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free. May 21, 2019 New Super-Microsurgical Procedure May Prevent Lymphedema in Breast Cancer Patients March 2, 2020 Surgeons Use Tissue From Cancer Survivor’s Love Handles For Rare Type... February 27, 2020 Load more HOT NEWS UK health inequalities: 20,000 more cancer cases a year in the... FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer COVID-19 Testing: What you need to know. Second Interim Analysis Shows OS Improvement with Adjuvant Olaparib for Germline...
